Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Hypogonadism
Interventions
DRUG

Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo

"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~1. Placebo (hypogonadism after leuprorelide injection)~2. Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~3. Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~4. No treatment."

Trial Locations (1)

8000

Medical department M and Investigational Laboratories, Aarhus C

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT00613288 - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism | Biotech Hunter | Biotech Hunter